|
|
|
| Irreversible electroporation plus chemotherapy versus chemotherapy alone as treatments for patients with locally advanced pancreatic cancer |
| Shan-Shuo Liu a , b , Hai-Yu Wang a , b , Ying Sun a , b , Ya-Wen Zou a , b , Zhi-Gang Ren a , b , Xin-Hua Chen c , Zu-Jiang Yu a , b , ∗ |
a Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
b Gene Hospital of Henan Province, Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
c Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou 310003, China
∗ Corresponding author at: Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
E-mail address: johnyuem@zzu.edu.cn (Z.-J. Yu). |
|
|
|
|
Abstract Pancreatic cancer is a major health problem worldwide, with a high incidence and mortality rate. It is estimated that it has become the sixth leading cause of cancer-related death in China and the fourth leading cause of cancer-related death globally [1]. For patients with locally advanced pancreatic cancer (LAPC), there are no standard treatment options. National Comprehensive Cancer Network (NCCN) guidelines define LAPC as that affecting the superior mesenteric artery (SMA) or the celiac axis (CA) more than 180 ° or nonrepairable infiltration of the superior mesenteric vein (SMV) or portal vein (PV). Although chemotherapy is a treatment option for these patients, the response rates are extremely low and survival benefits are limited [2]. As an emerging local tumor ablation technique, irreversible electroporation (IRE) works by inducing permanent cell membrane porosity through high voltage and microsecond pulses. Because of its lack of thermal effect, it can cause permanent cell death without damaging the surrounding tissues, which is a good option for tumors with large blood vessels, nerves and important tissue structures around the tumors. Additionally, the survival time of patients with LAPC is limited by radiotherapy or chemotherapy alone, and an adjuvant or consolidated local treatment is needed clinically to provide longer local control to relieve pain and possibly improve the survival of LAPC patients. More importantly, IRE allows larger blood vessels to remain intact, and activated antigen-presenting cells can infiltrate lesions and deliver infiltrating tumor fragments to the lymph nodes in place which activates adaptive immune system [3,4].
|
|
|
|
|
|
|
|
|
2022, Vol. 21 
